Our study has indeed revealed a notable trend where patients harboring combined mutations in TP53 and KRAS genes exhibit a higher likelihood of relapse following surgical intervention.
← all excerpts
Combined KRAS and TP53 mutation in patients with colorectal cancer enhance chemoresistance to promote postoperative recurrence and metastasis.
1
—
—